<code id='CEC7C41993'></code><style id='CEC7C41993'></style>
    • <acronym id='CEC7C41993'></acronym>
      <center id='CEC7C41993'><center id='CEC7C41993'><tfoot id='CEC7C41993'></tfoot></center><abbr id='CEC7C41993'><dir id='CEC7C41993'><tfoot id='CEC7C41993'></tfoot><noframes id='CEC7C41993'>

    • <optgroup id='CEC7C41993'><strike id='CEC7C41993'><sup id='CEC7C41993'></sup></strike><code id='CEC7C41993'></code></optgroup>
        1. <b id='CEC7C41993'><label id='CEC7C41993'><select id='CEC7C41993'><dt id='CEC7C41993'><span id='CEC7C41993'></span></dt></select></label></b><u id='CEC7C41993'></u>
          <i id='CEC7C41993'><strike id='CEC7C41993'><tt id='CEC7C41993'><pre id='CEC7C41993'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:explore    Page View:1
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In